Thomas Kipps, MD, PhD, UC San Diego Moores Cancer Center, La Jolla, CA, discusses the results of a Phase I/II study investigating the use of zilovertamab and ibrutinib in patients with chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL) (NCT03088878), explaining the mechanism of action of zilovertamab. Zilovertamab targets and inhibits the activity of the survival-promoting ROR1 protein expressed by CLL and MCL cells. Combining zilovertamab and ibrutinib treatment may therefore benefit patients who may fail to develop strong and durable responses to either treatment separately. Early Phase I/II trial results on this drug combination are promising, with ibrutinib treatment improving progression-free survival in patients with MCL and CLL – even those with relapsed/refractory (R/R) disease or high-risk genetic lesions such as tp53 alterations and del(17p). Dr Kipps highlights that the treatment landscape for patients with CLL and MCL may change radically, as traditionally high-risk groups gain access to targeted therapies that may significantly improve their outcomes. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть